CNTB News and Press, Connect Biopharma Holdings Limited From 11/22/21

Connect Biopharma (NASDAQ:CNTB) has appointed Steven Chan as Chief Financial Officer (CFO), succeeding Eric Hall who served as Interim CFO. Chan was previously CFO at global materials manufacturer Delphon Industries. For further details see: Connect Biopharma hires new CFO

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic...

Shares of Connect Biopharma (CNTB -54.0%) are down precipitously today following the company's after the bell announcement yesterday on phase 2 results for its lead candidate, CBP-201, for atopic dermatitis. Shares are down even though the company said the primary efficacy endpoint ...

Gainers: Greenland Technologies Corporation (NASDAQ:GTEC) +71%. Longeveron (NASDAQ:LGVN) +37%. Aurora (NASDAQ:AUR) +31%. Bakkt (NYSE:BKKT) +26%. FedNat Holding Company (NASDAQ:FNHC) +18%. UWM Holdings Corporation (NYSE:UWMC) +18%. SCYNEXIS (NASDAQ:SCYX) +16%. Kornit (NASDAQ:KRNT) +15%. Aspira...

Shares of Connect Biopharma (NASDAQ: CNTB) were crashing 51.8% lower as of 11:31 a.m. ET on Friday. The big decline came after the company reported top-line results on Thursday from a phase 2 clinical study evaluating CBP-201 administered subcutaneously (an injection under the skin)...

Gainers: Longeveron (NASDAQ:LGVN) +36%, SCYNEXIS (NASDAQ:SCYX) +16%, Context Therapeutics (NASDAQ:CNTX) +15%, Akoya Biosciences (NASDAQ:AKYA) +15%, Aspira Women's Health (NASDAQ:AWH) +15%. Losers: Connect Biopharma (NASDAQ:CNTB) -54%, Flora Gr...

Connect Biopharma (NASDAQ:CNTB) has completed full enrollment of the Phase 2 clinical trial evaluating CBP-307 in adult patients with moderate-to-severe Ulcerative Colitis (UC). Shares down 36.4% premarket at $7.70. This global, phase 2 trial is being conducted at multiple sites, in...

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic...

Connect Biopharma (NASDAQ:CNTB) announced that its lead candidate CBP-201 met the primary efficacy endpoint in a Phase 2 study involving adults with moderate-to-severe atopic dermatitis (AD). Connect (CNTB) shares are trading ~22.4% lower in the post-market. Based on a scale me...

Primary endpoint met with all three CBP-201 arms achieving significant improvements Significant improvements also reported for key secondary endpoints including other measures of skin clearance and itch with CBP-201 300mg every two weeks ( Q2W) arm The Company intend...